IC
FTH

Ikarian Capital’s Faeth Therapeutics FTH Stock Holding History

Ikarian Capital’s Portfolio FTH Stock Details FTH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$200K Sell
6,351
-15,000
-70% -$300K 0.02% 141
2025
Q4 		$228K Sell
21,351
-1,146
-5% -$11.1K 0.02% 151
2025
Q3 		$213K Hold
22,497
– – 0.02% 151
2025
Q2 		$193K Sell
22,497
-1
-0% -$7 0.04% 113
2025
Q1 		$177K Sell
22,498
-10,000
-31% -$95.1K 0.02% 142
2024
Q4 		$319K Sell
32,498
-2
-0% -$20 0.04% 140
2024
Q3 		$389K Hold
32,500
– – 0.05% 121
2024
Q2 		$403K Buy
+32,500
New +$676K 0.07% 98

Other funds holding FTH

VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
SC
Stempoint Capital New York $522M AUM 281.95% 1-Year Est. Return
CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $437M AUM
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return

Ikarian Capital's FTH Position: Q1 2026 in Review

Ikarian Capital reduced its Faeth Therapeutics (FTH) stake by 70% in Q1 2026, selling an estimated $300K and leaving 6,351 shares worth $200K. The position accounts for 0.02% of the portfolio, ranked #141.

Ikarian Capital first reported a position in FTH in Q2 2024 and has held it in 8 quarters since. The position peaked at $403K in Q2 2024. 30 funds tracked by Wall St. Rank hold FTH as of Q1 2026.

  • Ikarian Capital held 6,351 shares of Faeth Therapeutics worth $200K as of Q1 2026.
  • Ikarian Capital sold 15,000 Faeth Therapeutics shares in Q1 2026, an estimated $300K.
  • Faeth Therapeutics made up 0.02% of Ikarian Capital's portfolio in Q1 2026, its #141 holding.
  • Ikarian Capital first reported a position in Faeth Therapeutics in Q2 2024 and has held it in 8 quarters since.
  • Ikarian Capital's Faeth Therapeutics position peaked at $403K in Q2 2024.
  • 30 funds tracked by Wall St. Rank held Faeth Therapeutics as of Q1 2026.

Based on Ikarian Capital's 13F filing for Q1 2026, filed 15 May 2026.